氨溴索静脉给药防治新生儿肺透明膜病的系统评价

陈小红;苏娜;唐榕;尹茜;徐珽

中国药学杂志 ›› 2012, Vol. 47 ›› Issue (10) : 771-776.

PDF(2258 KB)
PDF(2258 KB)
中国药学杂志 ›› 2012, Vol. 47 ›› Issue (10) : 771-776.
儿科药学专栏

氨溴索静脉给药防治新生儿肺透明膜病的系统评价

  • 陈小红,苏娜,唐榕,尹茜,徐珽*
作者信息 +

A Systematic Review of Ambroxol Administered Intravenously for Infant Hyaline Membrane Disease

  • CHEN Xiao-hong,SU Na,TANG Rong,YIN Xi,XU Ting*
Author information +
文章历史 +

摘要

目的 系统评价氨溴索静脉给药防治新生儿肺透明膜病(hyaline membrane disease,HMD)的疗效和安全性。方法 计算机检索Cochrane图书馆、PubMed、Embase、ISI、CBM、CNKI、VIP、万方数据库,纳入氨溴索组静脉给药对比常规药物治疗新生儿肺透明膜病的随机对照试验(RCT),对纳入的随机对照试验进行方法学质量评价和Meta分析。结果 氨溴索组对比常规组对于新生儿肺透膜病共纳入17个RCT,均为中文文献,方法学质量均为C级,共1 372例患者。Meta分析结果显示:所有用于疗效评价的指标,包括新生儿肺透明膜病发生率[RR 0.29,95%CI(0.20,0.43),P<0.000 01]、新生儿肺透明膜病死亡率[RR 0.24,95%CI(0.13,0.45),P<0.000 1]、静脉给药治疗新生儿肺透明膜病总有效率[RR 2.42,95%CI(1.85,3.17),P<0.000 01]、新生儿肺透明膜病并发症发生率[RR 0.20,95%CI(0.11,0.37),P<0.000 01]、新生儿肺透明膜病胸部X线的变化[RR 2.81,95%CI(2.06,3.82),P<0.000 01]。氨溴索组均优于常规治疗组。另外,氨溴索组在血气氧合指标改善,住院时间,机械通气时间也优于常规治疗组且未出现明显的不良反应。结论 基于当前临床证据,氨溴索对比其他新生儿肺透明膜病常规治疗方法,能够更好的降低新生儿肺透明膜病的发生率,死亡率以及改善并发症的发生和胸部病理情况。在安全性发面,氨溴索组和常规治疗组均无明显不良反应,说明氨溴索治疗安全性较好。

关键词

氨溴索 / 新生儿肺透明膜病 / 新生儿呼吸窘迫综合征 / Meta分析 / 循证医学

引用本文

导出引用
陈小红;苏娜;唐榕;尹茜;徐珽. 氨溴索静脉给药防治新生儿肺透明膜病的系统评价[J]. 中国药学杂志, 2012, 47(10): 771-776
CHEN Xiao-hong;SU Na;TANG Rong;YIN Xi;XU Ting. A Systematic Review of Ambroxol Administered Intravenously for Infant Hyaline Membrane Disease[J]. Chinese Pharmaceutical Journal, 2012, 47(10): 771-776

参考文献

[1] LI H X,WEI Q F,HUANG Z G. Curative effect observation of ambroxol to prevent premature infant hyaline membrane disease [J]. J Qiqihaer Med Coll(齐齐哈尔医学院学报), 2008,29(01):27-28.

[2] JIN H Z, HUANG D M, GUAN X J. Practice Neonatology(实用新生儿学)[M]. 3nd ed. Beijing : People's Medical Publishing House, 1997: 422-423.

[3] FENG C F . Curative effect observation of large dose of ambroxol to prevent premature infant hyaline membrane disease [J]. Guangxi Med J(广西医学), 2009, 31(8):1123-1124.

[4] CHEN J B,ZHANG H X . Curative effect of ambroxol hydrochloride to treat premature infant hyaline membrane disease [J]. China Modern Doctor(中国现代医生), 2008,46(3): 94.

[5] LI Y X,XU H . Curative effect observation on large dose of ambroxol hydrochloride to prevent premature infant hyaline membrane disease[J]. J Henan Univ Sci Technol(Med Sci)(河南科技大学学报:医学版), 2008,26(1): 49-50.

[6] WAN J,LING L,XU J S, et al. Use of ambroxol in prevention of pulmonary hyaline membrane disease of premature infants[J]. Jiangsu Med J(江苏医药),2003,29(8):567-568.

[7] KE H,LIANG C,TANG Y. Observation of mucosolvan to prevent premature infant hyaline membrane disease[J]. Acta Acad Med Guangzhou(广州医学院学报),2004,32(1):78-79.

[8] YANG L J,LIU S,LI Y X, et al. Clinical analysis of mucosolvan to prevent premature infant hyaline membrane disease at early stage[J]. Zhejiang Clin Med J(浙江临床医学),2005,7(11):70.

[9] LIN M X,HUANG Y H,WENG C H,et al. The study on large dose ambroxol hydrochloride combining variant flow rate continuous positive airway by nasal mask to neonatal hyaline membrane disease[J]. Chin Matern Child Health Care(中国妇幼保健),2007,22(6):801-803.

[10] PAN H X,LIN R H,GUO Y T,et al. Curative effect observation on large dose of ambroxol hydrochloride to treat premature infant hyaline membrane disease[J]. Public Med Forum Mag(基层医学论坛),2007,11(9):799-801.

[11] HUANG B X,ZHANG S L,XU G P, et al. Curative effect observation of 40 cases using mucosolvan to prevent premature infant hyaline membrane disease[J]. Mod Med Health(现代医药卫生),2007,23(6):814-815.

[12] SHI M F,ZONG X M . Clinical observation of mucosolvan to treat infant hyaline membrane disease[J]. West China Med J(华西医学),2007,22(1):137-138.

[13] CHEN X,HUANG T W,XIE K K . Curative effect observation of ncpap combining large dose ambroxol hydrochloride to treat neonatal hyaline membrane disease[J]. Mod Hosp(现代医院),2008,8(05):29-31.

[14] HONG M,ZHEN H . Experience of 68 cases using large dose of ambroxol to prevent premature infant hyaline membrane disease [J]. Guangxi Med J(广西医学),2008,30(4): 513-514.

[15] YUAN X Y,ZHU Y,GAO Y R . Clinical analysis of 43 cases using mucosolvan to prevent premature infant hyaline membrane disease[J]. China Foreign Medical Treatment(中外医疗),2008,6(15):103.

[16] HAN L R,DAI Y . Clinical observation of using mucosolvan combined with NCPAP treat premature infan (Ⅰ~Ⅱ grade) hyaline membrane disease [J]. Mod J Integr Tradit Chin West Med (现代中西医结合杂志),2008,17(24):3807.

[17] ZHANG Y L,LI J Y,XU M H . Curative effect observation of 63 cases of mucosolvan prevent premature infant hyaline membrane disease [J]. J Zhengzhou Univ (Med Sci )(郑州大学学报医学版), 2008,43(05):1035-1036.

[18] WANG Y H . Clinical analysis of ambroxol hydrochloride to prevent premature infant hyaline membrane disease[J]. China Modern Doctor(中国现代医生), 2008,46(29):82,95.

[19] ZHANG L . Ambroxol prevents premature infant pulmenary hyaline membrane disease[J]. J Shanghai Med Univ (上海医科大学学报),2000,27(6): 509-510,513.

[20] LIN G Y, ZENG H, LU J . Effect on the prevention of hyalinemembrane disease inpremature newborns by using mucosolvan at different times[J]. Chin Emerg Med(中华急诊医学杂志),2003,12(04):252.
PDF(2258 KB)

Accesses

Citation

Detail

段落导航
相关文章

/